Imipenem
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Imipenem: From Bacterial Infections to Staphylococcus Aureus Infection
One-Sentence Summary
Imipenem is a carbapenem antibiotic originally developed to treat severe, often multidrug-resistant, bacterial infections. Among 10 TxGNN-predicted indications in this evidence pack, Staphylococcus Aureus Infection has by far the strongest support — 13 clinical trials (including a completed Phase 4 combination trial) and 20 publications spanning four decades — though this represents an extension of Imipenem’s existing antibacterial spectrum rather than a truly novel repurposing. The model’s single highest-scoring prediction (diffuse scleroderma) is explicitly flagged in the evidence pack as a knowledge-graph artifact with no supporting evidence and is not a viable candidate.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally available — Imipenem is not currently marketed in this jurisdiction (0 licenses on file); known pharmacologically as a carbapenem antibiotic for severe bacterial infections |
| Predicted New Indication | Staphylococcus Aureus Infection (strongest-evidence candidate among 10 predictions in this pack) |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L2 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed, formally sourced mechanism-of-action data is currently a documented gap (see DG002 below). However, the evidence pack’s own rationale annotations consistently describe Imipenem as a carbapenem β-lactam antibiotic that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins (PBPs), giving it a broad spectrum of activity against many Gram-positive and Gram-negative organisms.
Because the original indication for Imipenem is bacterial infection in general, its predicted activity against Staphylococcus aureus infection is not a mechanistic leap into a new disease category — it is a direct application of its existing antibacterial mechanism. This is reflected in the evidence: in vitro susceptibility data, animal infection models (endocarditis, endophthalmitis), and a completed Phase 4 trial (NCT00871104) evaluating fosfomycin plus imipenem against MRSA endocarditis versus vancomycin. The main caveat is that Imipenem alone has limited activity against methicillin-resistant strains (MRSA), so most of the higher-quality evidence involves combination regimens (with fosfomycin or linezolid) rather than monotherapy.
By contrast, several other predictions in this pack (diffuse scleroderma, paranasal sinus neoplasm, eosinophilia-myalgia syndrome) are explicitly annotated in the rationale data as having no plausible mechanistic link to an antibacterial drug and are treated as knowledge-graph embedding artifacts rather than genuine repurposing signals.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00871104 | Phase 4 | Completed | 50 | Fosfomycin plus imipenem vs. vancomycin for MRSA infective endocarditis |
| NCT01356472 | Phase 4 | Unknown | 60 | Linezolid alone vs. combined with carbapenem against MRSA in ventilator-associated pneumonia |
| NCT03583333 | Phase 3 | Completed | 274 | Imipenem/cilastatin/relebactam vs. piperacillin/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia |
| NCT00707239 | Phase 2 | Terminated | 108 | Tigecycline vs. imipenem/cilastatin for hospital-acquired pneumonia |
| NCT04292054 | Phase 3 | Recruiting | 506 | Antibiotic prophylaxis (incl. carbapenem-class regimens) for burn excision-graft surgery |
| NCT03218397 | N/A | Completed | 500 | Rapid identification/susceptibility testing (RAPIDS-GN) for Gram-negative bacteremia |
| NCT06174649 | N/A | Completed | 900 | Fast antibiotic susceptibility testing trial for Gram-negative bacteremia |
| NCT06634940 | N/A | Recruiting | 1000 | International surveillance of antimicrobial resistance in cirrhosis-related bacterial infections |
| NCT06044272 | N/A | Completed | 10000 | Retrospective antimicrobial resistance profiling, Meta State, Colombia (2018–2022) |
| NCT06743529 | N/A | Recruiting | 686 | Immediate vs. substantiated antibiotic therapy for suspected ventilator-associated pneumonia |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 3460521 | 1986 | Clinical treatment study | Antimicrob Agents Chemother | Imipenem-cilastatin evaluated in 23 patients with methicillin-sensitive and methicillin-resistant S. aureus infections |
| 33020155 | 2020 | Case commentary | Antimicrob Agents Chemother | Imipenem/cilastatin plus fosfomycin as a novel combination for refractory MRSA infection |
| 10588305 | 1999 | In vitro/in vivo study | J Antimicrob Chemother | Combined vancomycin and imipenem synergistic/additive against MRSA in most isolates tested |
| 20680368 | 2010 | In vitro/in vivo study | Eur J Clin Microbiol Infect Dis | Linezolid alone and combined with vancomycin/imipenem against S. aureus with reduced glycopeptide susceptibility |
| 7928812 | 1994 | Animal model | J Antimicrob Chemother | Comparative efficacy of imipenem, oxacillin, vancomycin for chronic foreign-body MSSA/MRSA infection |
| 23089756 | 2013 | Animal model | Antimicrob Agents Chemother | Imipenem (with fosfomycin/rifampin) evaluated in tissue-cage MRSA foreign-body infection model |
| 6421794 | 1983 | Animal model | J Antimicrob Chemother | Imipenem therapy of experimental S. aureus and S. faecalis endocarditis, comparable to nafcillin/penicillin combinations |
| 14618340 | 2003 | Animal model | Graefe’s Arch Clin Exp Ophthalmol | IV imipenem vs. ceftazidime/amikacin for S. aureus endophthalmitis in rabbit model |
| 22196394 | 2012 | Review | Int J Antimicrob Agents | Review of MRSA pathogenesis, key clinical trials, and antibacterial resistance implications |
| 36526264 | 2023 | Systematic review | J Glob Antimicrob Resist | AMR prevalence of E. coli and S. aureus among bacteremic patients in Africa |
Other Predicted Indications in This Evidence Pack
This candidate record (TW-DB01598-multi) contains 10 TxGNN predictions. For context, here is how the remaining nine compare:
| Disease | TxGNN Score | Evidence Level | Decision Stage | Recommendation |
|---|---|---|---|---|
| Diffuse scleroderma (rank 1, highest score) | 99.99% | L5 | S0 | Hold — no mechanistic link; likely KG artifact |
| Paratyphoid fever | 99.99% | L3 | S2 | Research Question |
| Salmonellosis | 99.99% | L3 | S2 | Research Question |
| Sinusitis | 99.99% | L3 | S1 | Research Question |
| Chronic rhinosinusitis | 99.98% | L4 | S0 | Hold |
| Typhoid fever | 99.98% | L3 | S2 | Proceed with Guardrails — carbapenems already used as last-line therapy for XDR S. Typhi |
| Chronic ethmoidal sinusitis | 99.98% | L4 | S0 | Hold |
| Paranasal sinus neoplasm | 99.98% | L5 | S0 | Hold — antibiotics have no antineoplastic mechanism; KG artifact |
| Eosinophilia-myalgia syndrome | 99.85% | L5 | S0 | Hold — non-infectious syndrome; no plausible mechanism |
Note that predicted TxGNN scores are uniformly high (all ≥99.8%) and do not by themselves discriminate evidence quality — several of the highest-scoring predictions (diffuse scleroderma, paranasal sinus neoplasm, eosinophilia-myalgia syndrome) are explicitly the weakest on independent clinical/mechanistic review.
Safety Considerations
Please refer to the SmPC for safety information. A drug-drug interaction query returned no results, and formal TFDA warning/contraindication text is currently a blocking data gap (DG001) that must be resolved before any safety-relevant (S1) evaluation can proceed.
Conclusion and Next Steps
Decision: Proceed with Guardrails (for Staphylococcus Aureus Infection specifically; other candidates in this pack are Research Question or Hold — see table above)
Rationale: Staphylococcus aureus infection is supported by a completed Phase 4 combination trial, decades of clinical and animal-model literature, and a mechanistically direct antibacterial rationale — but this is best framed as label/spectrum extension rather than novel repurposing, and Imipenem alone is not reliably effective against MRSA without a partner agent.
To proceed, the following is needed:
- TFDA warnings, contraindications, and full prescribing information (DG001 — blocking; currently missing)
- Formal mechanism-of-action documentation from DrugBank or equivalent source (DG002)
- Confirmation of local marketing/regulatory status, since this drug currently has zero authorizations on file in this jurisdiction
- A defined combination-therapy protocol (e.g., with fosfomycin or linezolid) if pursuing the MRSA-specific use case, since monotherapy evidence is weak for resistant strains
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.